Becker’s Healthcare is the leading source of cutting-edge business and legal information for healthcare industry leaders. This week, Becker’s Hospital Review published an article written by Dr. Patti Romeril, the system director of clinical pharmacy services at Memorial Hermann in Houston, TX.
In her article, Dr. Romeril argues how others in her position should be using post marketed drug safety data to help improve outcomes and decrease healthcare costs. As she points out, the reasons why analysis of adverse side effect data is essential are compelling:
$4.7 billion in reported adverse event side effect costs in 2013
Suspected $25 billion in true costs if unreported adverse drug events are considered
148,000 hospital admissions or readmissions as a result of adverse drug events
Making more informed drug choices using comprehensive and actionable adverse drug events data leads to improved patient safety and outcomes and reduced costs.
At AdverseEvents, we’ve been making these same arguments for quite some time. It’s incredibly fulfilling and exciting to see someone as prominent as Dr. Romeril urging her peers to step forward and use modern data and technologies to empower themselves and help save patient lives.
View the whole article here